Last reviewed · How we verify
Lidocaine gel 2%
Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.
Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Topical anesthesia of mucous membranes and skin, Relief of pain and itching associated with minor wounds, burns, and dermatological conditions.
At a glance
| Generic name | Lidocaine gel 2% |
|---|---|
| Also known as | lidocaine hydrochloride 2%, Xylocaine, lignocaine, A, Xylocaine jelly 2% |
| Sponsor | Atlantic Health System |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby blocking the generation and propagation of action potentials. This prevents sensory nerve transmission in the area where it is applied, resulting in local anesthesia. The gel formulation allows for topical application to mucous membranes and skin surfaces.
Approved indications
- Topical anesthesia of skin and mucous membranes
- Relief of pain and itching associated with minor cuts, wounds, and skin irritations
Common side effects
- Local irritation or burning at application site
- Allergic contact dermatitis
- Systemic toxicity (with excessive absorption)
Key clinical trials
- Closed Versus Open Lateral Internal Sphincterotomy for Chronic Anal Fissure (NA)
- This Clinical Trial Aims to Compare the Effectiveness of Two Intra-pulpal Cryotherapy Techniques-Endo-ice and Ice Sticks-in Decreasing Intra-operative Pain and Enhancing the Success of Local Anesthesia During Pulpectomy of Mandibular Molars With Symptomatic Irreversible Pulpitis. (NA)
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections (PHASE4)
- The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision (PHASE4)
- Cryotherapy as a Topical Anesthetic in Healthy Children (PHASE4)
- Effect of Injectable Hyaluronic Acid (HYADENT BG (HA)) on Bone Healing in Extraction Sockets (NA)
- Post-Menopause Skin Rejuvenation Study (PHASE4)
- Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine gel 2% CI brief — competitive landscape report
- Lidocaine gel 2% updates RSS · CI watch RSS
- Atlantic Health System portfolio CI